FarmaKology Newsletter - Issue #11
mySugr specializes in app-based, all-around care for people with diabetes made by people with diabetes. Our apps and services beautifully combine diabetes coaching, therapy management, diabetes supplies, automated data tracking, and seamless integration with a growing number of medical devices to ease the daily burden of living with diabetes.
Lilly's CYRAMZA® (ramucirumab) Becomes First FDA-Approved Biomarker-Driven Therapy in Patients with Hepatocellular Carcinoma
Eli Lilly and Company today announced that the U.S. Food and Drug Administration has approved CYRAMZA® (ramucirumab injection, 10 mg/mL solution), as a single agent, for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha-fetoprotein (AFP) of ≥400 ng/mL and have been treated with sorafenib.
Citius Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, provided a report today on the in vitro efficacy of Mino-Lok against various strains of Candida auris.
With Roche’s HER2-positive breast cancer drug Herceptin (trastuzumab) facing imminent patent expiration in the U.S., pharmaceutical firms are accelerating to develop antibody-drug conjugates (ADCs).
Pharmaceutical company Gilead says it will donate 2.4 million bottles of its HIV prevention drug to the Centers for Disease Control, That’s enough to protect 200,000 people from the disease for 11 years.